DoD Awards $16.4M Contract for Antidote Treatment to Meridian Medical Technologies
Contract Overview
Contract Amount: $16,411,500 ($16.4M)
Contractor: Meridian Medical Technologies, LLC
Awarding Agency: Department of Defense
Start Date: 2025-12-08
End Date: 2026-09-09
Contract Duration: 275 days
Daily Burn Rate: $59.7K/day
Competition Type: NOT AVAILABLE FOR COMPETITION
Pricing Type: FIRM FIXED PRICE
Sector: Healthcare
Official Description: 8511797933!ANTIDOTE TREATMENT
Place of Performance
Location: SAINT LOUIS, SAINT LOUIS County, MISSOURI, 63146
State: Missouri Government Spending
Plain-Language Summary
Department of Defense obligated $16.4 million to MERIDIAN MEDICAL TECHNOLOGIES, LLC for work described as: 8511797933!ANTIDOTE TREATMENT Key points: 1. Contract awarded to Meridian Medical Technologies, LLC for critical antidote treatment. 2. The Department of Defense (DoD) is the awarding agency, with the Defense Logistics Agency managing the contract. 3. The contract is for Biological Product (except Diagnostic) Manufacturing, with a firm fixed price. 4. The duration of the contract is 275 days, with an estimated completion date in September 2026.
Value Assessment
Rating: fair
The contract value is $16.4 million. Without comparable contracts or detailed cost breakdowns, assessing the pricing against similar products is difficult. The firm fixed price suggests an attempt to control costs, but the lack of competition raises concerns about optimal pricing.
Cost Per Unit: N/A
Competition Analysis
Competition Level: sole-source
This contract was not available for competition, indicating a sole-source award. This limits price discovery and potentially leads to higher costs for taxpayers as there is no competitive pressure to drive down prices.
Taxpayer Impact: The sole-source nature of this award may result in a higher cost to taxpayers compared to a competitively bid contract.
Public Impact
Ensures availability of critical antidote treatments for military personnel. Supports the biological product manufacturing sector. Potential for increased costs due to lack of competition. Reliability of supply chain for essential medical countermeasures.
Waste & Efficiency Indicators
Waste Risk Score: 50 / 10
Warning Flags
- Lack of competition
- Potential for overpricing
- Limited transparency in cost determination
Positive Signals
- Ensures critical supply
- Firm fixed price contract
Sector Analysis
The Biological Product (except Diagnostic) Manufacturing sector is vital for national security, providing essential medical countermeasures. Spending benchmarks are difficult to establish without specific product details, but consistent funding is typical for such critical supplies.
Small Business Impact
This contract was awarded to Meridian Medical Technologies, LLC, a specific company. There is no indication in the provided data whether small businesses were involved as subcontractors or if this award supports small business participation goals.
Oversight & Accountability
The contract is managed by the Defense Logistics Agency, part of the Department of Defense. Oversight would typically involve monitoring contract performance, delivery schedules, and adherence to the firm fixed price. The lack of competition warrants closer scrutiny of the justification for the sole-source award.
Related Government Programs
- Biological Product (except Diagnostic) Manufacturing
- Department of Defense Contracting
- Defense Logistics Agency Programs
Risk Flags
- Sole-source award limits competition and potentially increases cost.
- Lack of transparency in pricing justification.
- Potential for over-reliance on a single supplier.
- Need for robust agency oversight to ensure value.
Tags
biological-product-except-diagnostic-man, department-of-defense, mo, delivery-order, 10m-plus
Frequently Asked Questions
What is this federal contract paying for?
Department of Defense awarded $16.4 million to MERIDIAN MEDICAL TECHNOLOGIES, LLC. 8511797933!ANTIDOTE TREATMENT
Who is the contractor on this award?
The obligated recipient is MERIDIAN MEDICAL TECHNOLOGIES, LLC.
Which agency awarded this contract?
Awarding agency: Department of Defense (Defense Logistics Agency).
What is the total obligated amount?
The obligated amount is $16.4 million.
What is the period of performance?
Start: 2025-12-08. End: 2026-09-09.
What is the specific antidote treatment being procured, and what is its criticality to DoD operations?
The specific antidote treatment is identified as 'ANTIDOTE TREATMENT' under NAICS code 325414 (Biological Product Manufacturing). Its criticality is implied by its procurement by the Department of Defense, suggesting it is essential for personnel safety and operational readiness against biological threats. Further details on the specific threat it counters would clarify its exact importance.
What is the justification for awarding this contract on a sole-source basis, and how was the price determined?
The data states the contract was 'NOT AVAILABLE FOR COMPETITION,' indicating a sole-source award. The justification for this would typically involve factors like unique capabilities, urgent need, or lack of viable alternatives. The price was set as 'FIRM FIXED PRICE,' but without a competitive process, the determination of this price requires a thorough cost analysis by the agency to ensure fairness and value for taxpayer money.
How does the $16.4 million award compare to historical spending on similar antidote treatments, and what is the projected long-term cost?
Without specific details on the antidote or historical spending data for comparable items, a direct comparison is not possible. The $16.4 million is for a 275-day duration. The projected long-term cost would depend on future needs, potential for competition in subsequent awards, and any changes in manufacturing or raw material costs.
Industry Classification
NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing
Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP
Competition & Pricing
Extent Competed: NOT AVAILABLE FOR COMPETITION
Solicitation Procedures: ONLY ONE SOURCE
Pricing Type: FIRM FIXED PRICE (J)
Evaluated Preference: NONE
Contractor Details
Parent Company: Meridian Medical Technologies LLC
Address: 1945 CRAIG RD, SAINT LOUIS, MO, 63146
Business Categories: Category Business, Corporate Entity Not Tax Exempt, Limited Liability Corporation, Manufacturer of Goods, Not Designated a Small Business, Special Designations, U.S.-Owned Business
Financial Breakdown
Contract Ceiling: $16,411,500
Exercised Options: $16,411,500
Current Obligation: $16,411,500
Contract Characteristics
Commercial Item: COMMERCIAL PRODUCTS/SERVICES
Cost or Pricing Data: NO
Parent Contract
Parent Award PIID: SPE2DP26D0001
IDV Type: IDC
Timeline
Start Date: 2025-12-08
Current End Date: 2026-09-09
Potential End Date: 2026-09-09 00:00:00
Last Modified: 2025-12-09
More Contracts from Meridian Medical Technologies, LLC
- Atropine & Pralidoxime Chloride Injector, Single Dose Auto-Injectors — $82.2M (Department of Health and Human Services)
- FOR Other Functionsmeridian Medical Technologies, Inc — $28.8M (Department of Health and Human Services)
- Development and Delivery of FDA Approved — $25.9M (Department of Defense)
View all Meridian Medical Technologies, LLC federal contracts →
Other Department of Defense Contracts
- Federal Contract — $51.3B (Humana Government Business Inc)
- Lrip LOT 12 Advance Acquisition Contract — $35.1B (Lockheed Martin Corporation)
- SSN 802 and 803 Long Lead Time Material — $34.7B (Electric Boat Corporation)
- 200204!008532!1700!AF600 !naval AIR Systems Command !N0001902C3002 !A!N! !N! !20011026!20120430!008016958!008016958!834951691!n!lockheed Martin Corporation !lockheed Blvd !fort Worth !tx!76108!27000!439!48!fort Worth !tarrant !texas !+000026000000!n!n!018981928201!ac15!rdte/Aircraft-Eng/Manuf Develop !a1a!airframes and Spares !2ama!jast/Jsf !336411!E! !3! ! ! ! ! !99990909!B! ! !A! !a!n!r!2!002!n!1a!a!n!z! ! !N!C!N! ! ! !a!a!a!a!000!a!c!n! ! ! !Y! !N00019!0001! — $34.2B (Lockheed Martin Corporation)
- KC-X Modernization Program — $32.0B (THE Boeing Company)